Evolving Treatment Goals in Multiple Myeloma

In this segment, Dr. Hans Lee introduces the rapidly evolving treatment landscape in multiple myeloma and outlines how advances in immunotherapy, quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping management across newly diagnosed and relapsed disease. Dr. Muhamed Baljevic and Dr. Prashant Kapoor discuss how these advances have changed their treatment goals and clinical strategies, particularly as highly effective therapies move into earlier lines of treatment. The experts highlight the growing importance of achieving deep and durable responses while considering treatment duration, de-escalation, cumulative toxicity, treatment burden, and patient safety. Dr. Baljevic also emphasizes infection prevention and other supportive care considerations as increasingly important components of care with powerful immune-based therapies. The panel discusses how future treatment decisions may increasingly focus not only on maximizing efficacy, but also on identifying patients who may benefit from limited-duration approaches and determining when treatment intensity can be safely reduced without compromising disease control.